Michigan is currently home to 2199 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Controlling Locomotion Over Continuously Varying Activities for Agile Powered Prosthetic Legs
Recruiting
The overall goal of this project is to model human joint biomechanics over continuously-varying locomotion to enable adaptive control of powered above-knee prostheses. The central hypothesis of this project is that variable joint impedance can be parameterized by a continuous model based on measurable quantities called phase and task variables. This project will use machine learning to identify variable impedance functions from able-bodied data including joint perturbation responses across the p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2025
Locations: Rehab Lab, University of Michigan, Ann Arbor, Michigan
Conditions: Amputation
Different Doses of Naronapride Vs. Placebo in Gastroparesis
Recruiting
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/04/2025
Locations: Dr Falk Investigational Site, Flint, Michigan
Conditions: Gastroparesis
Blood Purification for the Treatment of Pathogen Associated Shock
Recruiting
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following: • Pathogen associated shock defined as: * The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation * Presence... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Septic Shock
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Recruiting
Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/04/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Aneurysmal Subarachnoid Hemorrhage
Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors
Recruiting
Demonstrate the feasibility of conducting an eight-week, (45 min/week), theory driven, virtually-delivered, tailored music-based relaxation (TiMBRe) intervention to decrease anxiety in adolescent and young adult (AYA) cancer survivors with clinically-relevant anxiety.
Gender:
ALL
Ages:
Between 15 years and 39 years
Trial Updated:
02/03/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Anxiety
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: The Cancer & Hematology Centers -Satellite Site, Grand Rapids, Michigan
Conditions: Myelofibrosis
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
Recruiting
The purpose of this study is to learn more about how to improve treatment of patients with diarrhea predominant Irritable Bowel Syndrome (IBS-D) symptoms.Included patients will be requested to answer online surveys and will undergo treatment with rifaximin. Hydrogen breath testing and biologic samples collection will also be completed during the study.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/03/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Recruiting
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
EDRN Prostate MRI Biomarker Study
Recruiting
The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: PSA, Prostate Cancer
A Pilot of a Personalized Circadian MHealth to Improve Sleep in Night Shift Workers
Recruiting
The goal of this project is to establish the evidence base for equitable accessibility and implementation of the precision sleep medicine mobile application, SHIFT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Henry Ford Columbus Medical Center, Novi, Michigan
Conditions: Shift Work Sleep Disorder
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Recruiting
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumor